Arrowstreet Capital’s BeOne Medicines Ltd ONC Stock Holding History

Arrowstreet Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$71.2M	Buy	249,758 +139,172	+126%	+$41M	0.03%	445
2026 Q1	$32.8M	Buy	110,586 +54,260	+96%	+$17.6M	0.02%	612
2025 Q4	$17.1M	Buy	56,326 +592	+1%	+$194K	0.01%	782
2025 Q3	$19M	Buy	55,734 +53,649	+2,573%	+$16.3M	0.01%	748
2025 Q2	$505K	Sell	2,085 -36,777	-95%	-$9.02M	﹤0.01%	1748
2025 Q1	$10.6M	Buy	+38,862	New	+$9.09M	0.01%	796
2021 Q1	–	Sell	-30,782	Closed	-$7.95M	–	2583
2020 Q4	$7.95M	Buy	+30,782	New	+$8.47M	0.01%	982
2018 Q4	–	Sell	-49,393	Closed	-$8.51M	–	1533
2018 Q3	$8.51M	Sell	49,393 -3,207	-6%	-$539K	0.02%	441
2018 Q2	$8.09M	Buy	+52,600	New	+$9.38M	0.02%	454

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arrowstreet Capital's ONC Position: Q2 2026 in Review

Arrowstreet Capital increased its BeOne Medicines Ltd (ONC) stake by 126% in Q2 2026, buying an estimated $41M and bringing the position to 249,758 shares worth $71.2M. The position accounts for 0.03% of the portfolio, ranked #445.

Arrowstreet Capital first reported a position in ONC in Q2 2018 and has held it in 9 quarters since. 283 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

Arrowstreet Capital held 249,758 shares of BeOne Medicines Ltd worth $71.2M as of Q2 2026.
Arrowstreet Capital bought 139,172 BeOne Medicines Ltd shares in Q2 2026, an estimated $41M.
BeOne Medicines Ltd made up 0.03% of Arrowstreet Capital's portfolio in Q2 2026, its #445 holding.
Arrowstreet Capital first reported a position in BeOne Medicines Ltd in Q2 2018 and has held it in 9 quarters since.
283 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.